Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 16/20 | 0.59 |
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16689484 | 1.00 | CASP1 (0.59) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL2619551 | 1.00 | CASP1 (0.59) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL30947821 | 0.92 | CASP1 (0.62) | CASP1SYKCTSLCTSBCTSS | |
| SCHEMBL13324038 | 0.92 | CTSL (0.58) | CTSKCTSLCTSBCTSS | |
| SCHEMBL14385711 | 0.90 | SYK (0.56) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL6078490 | 0.90 | SYK (0.56) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL6078485 | 0.90 | SYK (0.56) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL5033775 | 0.90 | PPARA (0.58) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL1093029 | 0.90 | PPARA (0.58) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL3004720 | 0.90 | PPARA (0.58) | CASP1SYKCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117304131-A | Alpha-carbonyl alkenyl ester compound, and preparation method and application thereof | 广州医科大学 | 2023-12-29 | — | — | CN | claimed |
| US-12583887-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12559521-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20240425547-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240409580-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2024-12-12 | — | — | US | disclosed |
| US-12139554-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-12122851-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| CN-118702713-A | N- (3-benzene)10Boric acid) -L-aspartic acid intermediate and preparation method thereof | 安徽普利药业有限公司 | 2024-09-27 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024097744-A2 | DNA-COMPATIBLE WITTIG OLEFINATION OF ON-DNA PEPTIDYL-YLIDES FOR DEVELOPMENT OF ON-DNA PEPTIDOMIMETICS THROUGH DIVERSITY-ORIENTED SYNTHESIS (DOS) | THE ROCKEFELLER UNIVERSITY (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2006117567-A2 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-28 | — | — | US | disclosed |
| US-20040106622-A1 | Aryl-substituted alicylic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1371646-A1 | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION COMPRISING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-12-17 | — | — | EP | disclosed |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-04-11 | — | — | US | disclosed |
| US-6018020-A | VIRICIDES WHICH ARE PROTEASE INHIBITORS AGAINST HEPATITIS C AND HEPATITIS G | HOFFMAN-LA ROCHE INC. (US) | 2000-01-25 | — | — | US | disclosed |
| US-5866684-A | Peptidyl inhibitors of viral proteases | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5430024-A | Peptides bearing N-terminal amidino moieties and their use as inhibitors of platelet aggregation | HOFFMANN-LA ROCHE INC. (US) | 1995-07-04 | — | — | US | disclosed |
| US-5294713-A | Inhibiting cell adhesion | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-03-15 | — | — | US | disclosed |
| US-5273982-A | An amidinoaryleneamidoalkylpiperazinyleneacetic acid | HOFFMANN-LA ROCHE INC. (US) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425547-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | CASP1 4534/4885SYK 4321/4885CTSK 889/4885 |
| US-20240409580-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | CASP1 4534/4885SYK 4321/4885CTSK 889/4885 |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | AVPR1A, AVPR2, AVPR1B | CASP1 1957/4885SYK 4471/4885CTSK 2623/4885 |
| US-12559521-B2 | PSMA imaging agents | KLK3, PSMA1, PSMA6 | CASP1 3525/4885SYK 4434/4885CTSK 824/4885 |
| US-12139554-B2 | PSMA imaging agents | FOLH1, KLK3, PSMA2 | CASP1 4534/4885SYK 4321/4885CTSK 889/4885 |
| US-12583887-B2 | PSMA imaging agents | KLK3, PSMA3, PSMA1 | CASP1 4037/4885SYK 4295/4885CTSK 965/4885 |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CASP3, IAPP, DPP3 | CASP1 6/4885SYK 3174/4885CTSK 762/4885 |
| US-12122851-B2 | PSMA imaging agents | FOLH1, KLK3, PSMA2 | CASP1 4534/4885SYK 4321/4885CTSK 889/4885 |
| US-20040106622-A1 | Aryl-substituted alicylic compound and medical composition comprising the same | ITGB3, ITGB1, ITGAL | CASP1 2322/4885SYK 787/4885CTSK 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.